Studies in the Area of Osteoarthritis Reported from SungKyunKwan University (Gastrointestinal Risk of Non-steroidal Anti-inflammatory Drugs and Gastroprotective Agents Used In the Treatment of Osteoarthritis In Elderly Patients: a Nationwide …)

2019 OCT 31 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Daily News -- Data detailed on Musculoskeletal Diseases and Conditions - Osteoarthritis have been presented. According to news reporting out of Gyeonggi-do, South Korea, by NewsRx editors, research stated, “Osteoarthritis is highly prevalent in older adults and often treated with nonsteroidal anti-inflammatory drugs (NSAIDs). COX-2-selective NSAIDs have been shown to offer better gastrointestinal (GI) safety benefits than non-selective NSAIDs (ns-NSAIDs).”

Financial support for this research came from postdoctoral research program of Sungkyunkwan University.

Our news journalists obtained a quote from the research from SungKyunKwan University, “However, most COX-2-selective NSAIDs have not been comprehensively evaluated for use in combination with gastroprotective agents (GPAs). This study compared the risk of adverse GI events in patients treated with COX-2-selective NSAIDs and ns-NSAIDs alone, or in combination with GPAs. We utilized National Health Insurance Claim Data collected from 2012 to 2015. Newly diagnosed patients with osteoarthritis (60 years or older) were included in this study. The study population was divided into two groups: 1) COX-2-selective NSAID treatment and 2) ns-NSAIDs treatment. Patients were followed-up for up to 6 months to determine whether GI events occurred. The Cox proportional hazards model was used to identify differences in risk. Subgroup analyses were conducted for monotherapies and combination treatments with GPAs. The number of subjects prescribed COX-2-selective NSAID and ns-NSAIDs were 20,868 (5.6%) and 353,494 (94.4%), respectively. After adjustment for confounding factors, COX-2-selective NSAID were safer than ns-NSAIDs (adjusted hazard ratio (aHR) = 0.80, 95% confidence interval (CI): 0.77 - 0.82). Use of GPAs with COX-2-selective NSAID was associated with a lower risk of GI events than use of ns-NSAIDs (aHR = 0.92, 95% CI: 0.87 - 0.97). Use of COX-2-selective NSAID was associated with a lower risk of GI adverse events than use of ns-NSAIDs as a monotherapy.”

According to the news editors, the research concluded: “Furthermore, COX-2-selective NSAID were safer than ns-NSAIDs in combination with GPAs.”

For more information on this research see: Gastrointestinal Risk of Non-steroidal Anti-inflammatory Drugs and Gastroprotective Agents Used In the Treatment of Osteoarthritis In Elderly Patients: a Nationwide Retrospective Cohort Study. International Journal of Clinical Pharmacology and Therapeutics, 2019;57(11):531-541. International Journal of Clinical Pharmacology and Therapeutics can be contacted at: Dustri-Verlag Dr Karl Feistle, Bahnhofstrasse 9 Postfach 49, D-82032 Deisenhofen-Muenchen, Germany.

Our news journalists report that additional information may be obtained by contacting E.K. Lee, SungKyunKwan University, School of Pharmacy, 2066 Seobu Ro, Suwon 03063, Gyeonggi Do, South Korea. Additional authors for this research include M.H. Han, J.H. Nam and E. Noh.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.5414/CP203377. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)